医疗到病床的PCSK9i启动计划对ASCVD重血管化的患者的LDL-C的影响
Daniel Lorenzatti1, Garred S Greenberg1, Annalisa Filtz1
1Division of Cardiology, Montefiore Health System/Albert Einstein College of Medicine, Bronx, New York, USA.
JACC. Advances
|August 20, 2025
概括
通过药物到床计划早期使用蛋白转化酶亚素/ 凯类型9抑制剂 (PCSK9i) 显著改善了患者在重血管化后的LDL- C目标. 这种方法改善了二次心血管疾病预防的脂质管理.
科学领域:
- 心脏病学
- 药理学
- 预防医学
背景情况:
- 低密度脂蛋白胆固醇 (LDL- C) 目标的实现仍然存在,尽管LDL- C降低在二次动脉样硬化心血管疾病 (ASCVD) 预防方面的已知好处.
- 在高风险患者中,最大限度地降低脂质治疗对于减少复发性心血管事件至关重要.
研究的目的:
- 通过药物到病床 (M2B) 计划评估早期蛋白转化酶亚素/素类型9抑制剂 (PCSK9i) 单克隆抗体 (mAb) 的疗效.
- 评估这种干预措施是否能改善ASCVD重血管化的患者的LDL- C目标.
主要方法:
- 一组接受冠状动脉或外周动脉再血管化的潜在患者通过M2B计划获得了指导方针推的PCSK9i mAbs.
- 患者接受了最大耐受度的他类药物治疗,LDL- C基线≥70 mg/ dL,并进行了至少6个月的随访.
- 与接受标准治疗的直接匹配的历史对照组进行了比较.
主要成果:
- 与对照组相比,PCSK9i mAb组 (n=72) 在6个月内显著提高LDL- C目标 (92% < 70 mg/ dL,79% < 55 mg/ dL).
- 在PCSK9i mAb组 (66%) 与对照组 (25%) 中,LDL- C的中位数降低显著.
- 基线LDL-C在PCSK9i mAb组 (96 mg/ dL) 低于对照组 (109 mg/ dL),P< 0.05.
结论:
- 通过专门的M2B计划提前实施指南推的PCSK9i mAbs有效地提高了LDL-C目标的实现.
- 这种策略对接受再血管化的已确诊ASCVD患者有益,改善了二次预防结果.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29


